You are here: Industry Insights > Amgen

News List

Amgen and AstraZeneca's experimental drug cuts asthma exacerbations by up to 71% pharmafile
September 08, 2017
An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca’s global biologics and research division
No need for 60%-plus discounts on Repatha, Amgen says, rolling out real-world data as backup fiercepharma
August 24, 2017
Amgen says new economic analysis of Repatha's outcomes study suggests that the drug is worth the $9,669 annual price tag.
Amgen and Humana partner for improved health outcomes and efficiency worldpharmanews
August 23, 2017
Two of the nation's leading health organizations, health and well-being company Humana Inc. and biotechnology company Amgen, have teamed up to identify opportunities to improve health outcomes and improve efficiency by...
Amgen collaborates with Humana to improve health outcomes biospectrumasia
August 22, 2017
The collaboration will initially target multiple serious conditions, including cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer.
'Dark money’ and drugs: Ohio pricing activists cry foul over secret donors fiercepharma
August 16, 2017
Drug pricing will be on the ballot this fall in Ohio, with proponents recently crying foul about "dark money" in politics.
Amgen falls short in Epogen patent appeal but Pfizer stumble delays competition fiercepharma
August 14, 2017
Despite a loss in appeals over a patent case, Amgen won't face Epogen biosim competition right away. (http://www.cafc.uscourts.gov)
What do kids think of their parents' RA? Amgen's new Enbrel push offers a few ideas fiercepharma
August 10, 2017
Amgen has launched a new DTC campaign for arthritis drug Enbrel featuring children who have parents with the disease.
Amgen, Allergan Submit Biosimilar Biologics License Application for ABP 980 americanpharmaceuticalreview
August 02, 2017
Amgen and Allergan announced the submission of a Biologics License Application (BLA) to the FDA for ABP 980
Amgen submits sBLA for Prolia in glucocorticoid-induced osteoporosis cphi-online
August 01, 2017
Results from the Phase III study included in the sBLA submission showed that treatment with Prolia for 12 months led to statistically significant greater gains in BMD at the lumbar spine and total hip compared to risedronate.
Amgen posts higher Q2 profit and sales, lifts 2017 earnings outlook firstwordpharma
July 26, 2017
Amgen reported Tuesday that net profit rose to $2.2 billion during the second quarter, up from $1.9 billion in the year-prior period.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page